Blockade of chemokine signaling in patients with multiple sclerosis

被引：60

作者：

Zipp, F.

Hartung, H-P.

Hillert, J.

Schimrigk, S.

Trebst, C.

Stangel, M.

Infante-Duarte, C.

Jakobs, P.

Wolf, C.

Sandbrink, R.

Pohl, C.

Filippi, M.

机构：

[1] Charite Univ Med Berlin, Neurosci Res Ctr, Inst Neuroimmunol, D-10098 Berlin, Germany

[2] Univ Dusseldorf, D-4000 Dusseldorf, Germany

[3] Karolinska Inst, Neurotec Dept, Stockholm, Sweden

[4] Ruhr Univ Bochum, Dept Neurol, St Josef Hosp, D-4630 Bochum, Germany

[5] Sch Med, Dept Neurol, Hannover, Germany

[6] Schering AG, Berlin, Germany

[7] Univ Hosp, Dept Neurol, Bonn, Germany

[8] Univ Milan, HSR, Milan, Italy

[9] Inst Sci, Dept Neurol, Neuroimaging Res Unit, Milan, Italy

来源：

NEUROLOGY | 2006年 / 67卷 / 10期

关键词：

D O I：

10.1212/01.wnl.0000244420.68037.86

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The CC chemokine receptor 1 (CCR1), expressed on macrophages and T cells, and its ligands, CCL3 and CCL5, are likely to play a role in MS pathology. In MS plaques, numerous CCR1-positive infiltrating macrophages and microglial cells, especially associated with CCL3, were found. 1 CCR1 has been associated with newly infiltrating monocytes in MS lesions.(2) The degree of leukocyte infiltration into the CNS during experimental autoimmune encephalomyelitis (EAE) was reduced on treatment with a specific CCR1 antagonist.(3) CCR1-deficient mice showed an attenuated EAE course.(4) A small-molecule antagonist of CCR1, BX 471, was able to reduce the severity of EAE(5) and delay heart transplant rejection. 6 Here, we investigated the safety, tolerability, and effects of BX 471, which was developed with a potential for oral therapy.

引用

页码：1880 / 1883

页数：4

共 12 条

[1] CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions [J].

Balashov, KE ;

Rottman, JB ;

Weiner, HL ;

Hancock, WW .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) :6873-6878

[2]

Ding ZQ, 2001, J LEUKOCYTE BIOL, V69, P458

[3] Effector stage CC chemokine receptor-1 selective antagonism reduces multiple sclerosis-like rat disease [J].

Eltayeb, S ;

Sunnemark, D ;

Berg, AL ;

Nordvall, G ;

Malmberg, Å ;

Lassmann, H ;

Wallström, E ;

Olsson, T ;

Ericsson-Dahlstrand, A .

JOURNAL OF NEUROIMMUNOLOGY, 2003, 142 (1-2) :75-85

[4] MAGNETIC-RESONANCE-IMAGING LESION ENLARGEMENT IN MULTIPLE-SCLEROSIS - DISEASE-RELATED ACTIVITY, CHANCE OCCURRENCE, OR MEASUREMENT ARTIFACT [J].

GOODKIN, DE ;

ROSS, JS ;

MEDENDORP, SV ;

KONESCSNI, J ;

RUDICK, RA .

ARCHIVES OF NEUROLOGY, 1992, 49 (03) :261-263

[5] A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection [J].

Horuk, R ;

Clayberger, C ;

Krensky, AM ;

Wang, ZH ;

Gröne, HJ ;

Weber, C ;

Weber, KSC ;

Nelson, PJ ;

May, K ;

Rosser, M ;

Dunning, L ;

Liang, M ;

Buckmann, B ;

Ghannam, A ;

Ng, HP ;

Islam, I ;

Bauman, JG ;

Wei, GP ;

Monahan, S ;

Xu, W ;

Snider, RM ;

Morrissey, MM ;

Hesselgesser, J ;

Perez, HD .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (06) :4199-4204

[6] Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1 [J].

Liang, M ;

Mallari, C ;

Rosser, M ;

Ng, HP ;

May, K ;

Monahan, S ;

Bauman, JG ;

Islam, I ;

Ghannam, A ;

Buckman, B ;

Shaw, K ;

Wei, GP ;

Xu, W ;

Zhao, Z ;

Ho, E ;

Shen, J ;

Oanh, H ;

Subramanyam, B ;

Vergona, R ;

Taub, D ;

Dunning, L ;

Harvey, S ;

Snider, RM ;

Hesselgesser, J ;

Morrissey, MM ;

Perez, HD ;

Horuk, R .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (25) :19000-19008

[7] A controlled trial of natalizumab for relapsing multiple sclerosis. [J].

Miller, DH ;

Khan, OA ;

Sheremata, WA ;

Blumhardt, LD ;

Rice, GPA ;

Libonati, MA ;

Willmer-Hulme, AJ ;

Dalton, CM ;

Miszkiel, KA ;

O'Connor, PW .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (01) :15-23

[8]

Miller DH, 1999, ANN NEUROL, V46, P850, DOI 10.1002/1531-8249(199912)46:6<850::AID-ANA7>3.0.CO

[9]

2-Q

[10]

Rottman JB, 2000, EUR J IMMUNOL, V30, P2372, DOI 10.1002/1521-4141(2000)30:8<2372::AID-IMMU2372>3.0.CO

← 1 2 →